Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)
This study has been completed.
First Posted: June 19, 2012
Last Update Posted: February 8, 2016
Information provided by (Responsible Party):